Cocrystal raises $5M from OPKO Health ahead of late-2026 norovirus data
What's the deal? Cocrystal PharmaDealroom has a profile for this one. Try Dealroom → has raised $5 million in a private placement from OPKO Health, a longtime investor now increasing its position. The financing is post-IPO equity.
Why now? The raise lands as Cocrystal advances toward Phase 1b data for its norovirus program, expected in late 2026.
What's the endgame? The capital supports Cocrystal's push to reach that clinical milestone, a key readout for its lead program.
The signal: An existing backer doubling down ahead of a data readout is a vote of confidence — but for a clinical-stage biotech, everything still hinges on the numbers due late this year.
Read more: aktiencheck.de
Image credit: foteih
Source: dealroom
